Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 43.09B P/E 62.63 EPS this Y 4.80% Ern Qtrly Grth -9.30%
Income 845.63M Forward P/E 46.77 EPS next Y 15.80% 50D Avg Chg 4.00%
Sales 3.78B PEG 4.33 EPS past 5Y 16.73% 200D Avg Chg 12.00%
Dividend N/A Price/Book 39.42 EPS next 5Y 10.85% 52W High Chg -8.00%
Recommedations 2.50 Quick Ratio 0.90 Shares Outstanding 82.31M 52W Low Chg 64.00%
Insider Own 0.94% ROA 22.77% Shares Float 81.39M Beta 1.33
Inst Own 95.94% ROE 63.25% Shares Shorted/Prior 2.38M/2.41M Price 519.18
Gross Margin 60.41% Profit Margin 22.34% Avg. Volume 454,379 Target Price 531.19
Oper. Margin 32.41% Earnings Date Oct 31 Volume 759,719 Change -2.46%
About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories, Inc. News
11/21/24 IDEXX Announces CFO Transition
11/19/24 IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
11/15/24 IDEXX Laboratories (NASDAQ:IDXX) shareholders have earned a 10% CAGR over the last five years
11/10/24 Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
11/07/24 Is IDEXX Laboratories (IDXX) The Best Pet Stock To Invest In According To Analysts?
11/06/24 Could The Market Be Wrong About IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Its Attractive Financial Prospects?
11/06/24 Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
11/05/24 A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback
11/01/24 Here’s Why Aristotle Focus Growth Strategy Sold IDEXX Laboratories (IDXX)
11/01/24 IDEXX Laboratories Inc (IDXX) Q3 2024 Earnings Call Highlights: Strong EPS Growth Amid Market ...
11/01/24 Q3 2024 IDEXX Laboratories Inc Earnings Call
10/31/24 CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results
10/31/24 IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket
10/31/24 Idexx (IDXX) Reports Q3 Earnings: What Key Metrics Have to Say
10/31/24 Calculating The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
10/31/24 Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates
10/31/24 Idexx: Q3 Earnings Snapshot
10/28/24 Seeking Clues to Idexx (IDXX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
10/25/24 Waters (WAT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10/24/24 Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
IDXX Chatroom

User Image briefingcom Posted - 23 hours ago

$IDXX: IDEXX Labs announces that Brian McKeon has decided to retire from IDEXX effective June 1, 2025 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241121073447IDXX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Nigela Posted - 4 days ago

Zillow Group, Inc. ( $Z) Shares Sold by Sumitomo Mitsui Trust Group Inc. Steward Partners Investment Advisory Makes New Investment in Wimi Hologram Cloud Inc. ( $WIMI ) Aptus Capital Advisors LLC Grows Position in IDEXX Laboratories, Inc. ( $IDXX)

User Image gaineous Posted - 6 days ago

$IDXX Popping the hood on this one.

User Image PenkeTrading Posted - 10/31/24

I found you an Oversold RSI (Relative Strength Index) on the daily chart of IDEXX Laboratories Inc. Is that bullish or bearish? $IDXX #RsiOversold #NASDAQ

User Image Benzinga Posted - 10/31/24

Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer- $IDXX

User Image GuardogJ Posted - 10/31/24

$ZOM wow $IDXX has dropped $45 today so I guess $ZOM is not doing too bad

User Image Thelonius_Stonk Posted - 10/31/24

$IDXX lower trendline

User Image EingeLTrade Posted - 10/31/24

IDEXX Laboratories Q3 2024 report Sales: $975.54M vs. $979.18M est. ❌ Adj. EPS: $2.79 Beats vs. $2.68 est. ✅ Expects 2024 Adjusted EPS Of: $10.37-$10.53 Versus Prior Guidance Of $10.31-$10.59 And Consensus Of $10.56 $IDXX

User Image Estimize Posted - 10/31/24

$IDXX reported 2.80 EPS and 975.54 revenue for Q3. http://www.estimize.com/intro/idxx?chart=historical&metric_name=eps&utm_content=IDXX&utm

User Image DonCorleone77 Posted - 10/31/24

$IDXX Idexx Laboratories narrows 2024 EPS view to $10.37-$10.53 from $10.31-$10.59 Consensus for 2024 EPS is $10.56. Lowers 2024 revenue view to $3.865M-$3.890M from $3.885B-$3.945B, consensus $3.92B.

User Image DonCorleone77 Posted - 10/31/24

$IDXX Idexx Laboratories reports Q3 EPS $2.80, consensus $2.68 Reports Q3 revenue $976M, consensus $979.18M. "IDEXX teams continued their strong execution in Q3 as demonstrated by solid net customer gains, continued growth in our premium IDEXX VetLab instrument installed base, and nearly 700 pre-orders of IDEXX inVue Dx Cellular Analyzer, which will begin shipping later in Q4," said CEO Jay Mazelsky. "Customers especially value IDEXX technology solutions like inVue Dx that provide meaningful clinical insights while giving time back to busy practice staff."

User Image Figaroke Posted - 10/28/24

$IDXX Fantastic business. If the valuation ever becomes reasonable, if will add this as a long-term position

User Image swingingtech Posted - 1 month ago

$DVN $SPOT $IDXX https://wallstreetwaves.com/highlighted-thursday-options-activity-dvn-spot-and-idxx/

User Image WeeklyTrader Posted - 1 month ago

Not the time to buy $IDXX! RSI: 42.17% 50-day MA: $487.93 200-day MA: $509.8

User Image WeeklyTrader Posted - 1 month ago

Let’s share our thoughts on $IDXX's decline! RSI: 40.6% 50-day MA: $487.74 200-day MA: $510.2

User Image EingeLTrade Posted - 09/27/24

A stock to hold for a few months, and you will know why😉 $IDXX

User Image Aigner_Andreas Posted - 2 months ago

TD SELL $IDXX at 517.06, Supp 469.01 Resis 517.06 R10 HiLo 68% T1Y 480 buy 2.3 DIV N/A #IDEXX Labo #stocks #trading #finance #market

User Image Alex_Hudson Posted - 2 months ago

$IDXX Price Cross Above 100 EMA.

User Image vu_jade Posted - 2 months ago

$IDXX ready for Comeback

User Image DomeniaSalvia Posted - 2 months ago

$IDXX IDEXX Laboratories remains a leader in veterinary diagnostics, with a strong focus on pet care and animal health. A must-watch in the healthcare space. Check out my website, link in bio.

User Image Villidj_Idjit Posted - 3 months ago

$IDXX at the middle of its (admittedly large, hahaha) Darvas Box.

User Image MyChicago Posted - 3 months ago

$ZOM Earning today, and new international partnership announced today. $IDXX $WOOF . These international partnerships are what will build Zomedica, just like $IDXX and other veterinarian companies. TIME TO BUY.

User Image MyChicago Posted - 3 months ago

$ZOM Earning today, and new international partnership announced today. $IDXX $WOOF . These international partnerships are what will build Zomedica, just like $IDXX and other veterinarian companies. TIME TO BUY.

User Image DonCorleone77 Posted - 3 months ago

$IDXX Idexx Laboratories cuts FY24 EPS view to $10.31-$10.59 from $10.82-$11.20 FY24 EPS consensus $11.05. Cuts FY24 revenue view to $3.885B-$3.945B from $3.895B-$3.965B, consensus $3.94B.

User Image DonCorleone77 Posted - 3 months ago

$IDXX Idexx Laboratories reports Q2 EPS $2.44 , consensus $2.88 Reports Q2 revenue $1.00B, consensus $1.01B. "Continued high levels of execution from IDEXX teams drove solid global growth and strong operational performance in Q2," said CEO Jay Mazelsky. "These results reflect the benefits that IDEXX customers gain from adopting our innovative, multi-modality testing platforms and solutions. Veterinarians appreciate the deep diagnostics insights generated by IDEXX solutions, which help them deliver better patient outcomes and seamless workflow for better business results. This value-added partnership, supported by IDEXX innovation, sets a strong foundation for long-term growth through higher standards of pet healthcare."

User Image epsguid Posted - 3 months ago

$IDXX reported earnings of $2.44, consensus was $2.87 via @eWhispers #epsmiss http://eps.sh/d/idxx

User Image Estimize Posted - 3 months ago

$IDXX misses the Estimize EPS Consensus by 49c and the Estimize Revenue Consensus by $10.09M. Reports FQ2 earnings of $2.44 EPS and $1B... http://www.estimize.com/idxx/fq2-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image Stock_Titan Posted - 3 months ago

$IDXX IDEXX Laboratories Announces Second Quarter Results https://www.stocktitan.net/news/IDXX/idexx-laboratories-announces-second-quarter-50qpdf0wrj6h.html

User Image Estimize Posted - 3 months ago

$IDXX reports before the open tomorrow, Estimize Consensus +0.05 EPS and +7.01M Revs compared to WS http://www.estimize.com/idxx/fq2-2024?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

User Image NVDAMillionaire Posted - 07/31/24

$IDXX IDEXX Laboratories (NASDAQ:IDXX): A Comprehensive Analysis of a Leading Animal Health Innovator http://beyondspx.com/2024/07/31/idexx-laboratories-nasdaqidxx-a-comprehensive-analysis-of-a-leading-animal-health-innovator/

Analyst Ratings
Piper Sandler Neutral Aug 14, 24
BTIG Buy Jul 25, 24
Stifel Hold Jun 24, 24
Morgan Stanley Overweight May 14, 24
Barclays Overweight May 2, 24
JP Morgan Overweight Feb 6, 24
Barclays Overweight Feb 6, 24
Piper Sandler Neutral Jan 30, 24
Goldman Sachs Buy Jan 17, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
POLEWACZYK JAMES F Executive Vice Presi.. Executive Vice President Dec 07 Sell 521.77 11,636 6,071,316 10,050 12/08/23
POLEWACZYK JAMES F Executive Vice Presi.. Executive Vice President Dec 07 Option 247.86 11,636 2,884,099 21,686 12/08/23
MAZELSKY JONATHAN JAY President and CEO President and CEO Dec 04 Sell 513.23 7,128 3,658,303 79,233 12/06/23
MAZELSKY JONATHAN JAY President and CEO President and CEO Dec 04 Option 79.54 13,424 1,067,745 86,361 12/06/23
Lane Michael Executive Vice Presi.. Executive Vice President Nov 07 Option 129.24 1,728 223,327 5,774 11/08/23
MAZELSKY JONATHAN JAY President and CEO President and CEO Aug 31 Sell 512.01 13,424 6,873,222 72,925 09/05/23
MAZELSKY JONATHAN JAY President and CEO President and CEO Aug 31 Option 79.54 13,424 1,067,745 86,349 09/05/23
POLEWACZYK JAMES F Executive Vice Presi.. Executive Vice President Aug 29 Sell 510.23 22,909 11,688,859 10,038 08/31/23
POLEWACZYK JAMES F Executive Vice Presi.. Executive Vice President Aug 29 Option 141.69 16,909 2,395,836 32,947 08/31/23
Lane Michael Executive Vice Presi.. Executive Vice President Aug 03 Sell 510 16,027 8,173,770 4,034 08/07/23
Lane Michael Executive Vice Presi.. Executive Vice President Aug 03 Option 175.6 16,027 2,814,341 20,061 08/07/23
AYERS JONATHAN W Director Director May 18 Option 79.54 20,000 1,590,800 147,039 05/22/23
AYERS JONATHAN W Director Director May 18 Sell 491.23 20,000 9,824,600 137,039 05/22/23
AYERS JONATHAN W Director Director May 09 Option 178.26 560 99,826 141,894 05/11/23
Underberg Sharon E. EVP, GC & Corporate.. EVP, GC & Corporate Secretary May 05 Option 206.94 483 99,952 4,245 05/08/23
SZOSTAK M ANNE Director Director May 05 Sell 474.99 2,000 949,980 4,700 05/08/23
MCKEON BRIAN P EVP, CFO and Treasur.. EVP, CFO and Treasurer May 05 Option 178.26 560 99,826 29,605 05/08/23
Vandebroek Sophie V. Director Director May 04 Sell 469.02 2,187 1,025,747 872 05/05/23
Vandebroek Sophie V. Director Director May 04 Option 206.62 2,187 451,878 3,059 05/05/23
MAZELSKY JONATHAN JAY President and CEO President and CEO May 04 Option 178.26 560 99,826 73,301 05/05/23
Turner Kathy V Senior Vice Presiden.. Senior Vice President Feb 14 Sell 504.16 2,000 1,008,320 7,380 02/16/23
Turner Kathy V Senior Vice Presiden.. Senior Vice President Feb 14 Option 13.26 2,732 36,226 9,380 02/16/23
SZOSTAK M ANNE Director Director Dec 02 Option 160.28 2,000 320,560 2,000 12/06/22
SZOSTAK M ANNE Director Director Dec 02 Sell 428.55 740 317,127 1,260 12/06/22
MAZELSKY JONATHAN JAY President & CEO President & CEO Nov 14 Sell 434.65 10,500 4,563,825 70,805 11/16/22
MAZELSKY JONATHAN JAY President & CEO President & CEO Nov 14 Option 62 18,998 1,177,876 81,305 11/16/22
Turner Kathy V Senior Vice Presiden.. Senior Vice President Nov 10 Option 192.6 13,877 2,672,710 15,490 11/14/22
Turner Kathy V Senior Vice Presiden.. Senior Vice President Nov 10 Sell 422.91 13,877 5,868,722 6,923 11/14/22
MAZELSKY JONATHAN JAY President & CEO President & CEO Nov 07 Option 52 24,002 1,248,104 75,537 11/09/22
MAZELSKY JONATHAN JAY President & CEO President & CEO Nov 07 Sell 382.07 13,230 5,054,786 62,307 11/09/22
Underberg Sharon E. EVP, GC & Corp. Secr.. EVP, GC & Corp. Secretary Feb 17 Option 206.94 483 99,952 2,987 02/18/22
MCKEON BRIAN P Executive VP & CFO Executive VP & CFO Feb 16 Option 141.60 706 99,970 28,154 02/17/22
AYERS JONATHAN W Director Director Feb 15 Sell 509.7 250 127,425 629,490 02/17/22
MCKEON BRIAN P Executive VP & CFO Executive VP & CFO Nov 08 Option 67.85 16,310 1,106,634 32,627 11/10/21
MCKEON BRIAN P Executive VP & CFO Executive VP & CFO Nov 08 Sell 629.21 16,310 10,262,415 26,317 11/10/21
Turner Kathy V Senior Vice Presiden.. Senior Vice President May 26 Sell 547 2,900 1,586,300 4,866 05/26/21
AYERS JONATHAN W Director Director May 20 Option 79.54 7,632 607,049 661,333 05/20/21
AYERS JONATHAN W Director Director May 12 Sell 541.74 512 277,371 653,701 05/12/21
HENDERSON REBECCA M Director Director Feb 25 Option 160.28 3,046 488,213 17,742 02/25/21
HENDERSON REBECCA M Director Director Feb 25 Sell 513.41 3,046 1,563,847 14,696 02/25/21
Claflin Bruce L. Director Director Feb 18 Option 122.64 7,027 861,791 7,331 02/18/21
Claflin Bruce L. Director Director Feb 18 Sell 537.04 7,331 3,937,040 02/18/21
MCKEON BRIAN P Executive VP & CFO Executive VP & CFO Feb 17 Option 0 2,642 27,356 02/17/21
MCKEON BRIAN P Executive VP & CFO Executive VP & CFO Feb 17 Sell 539.58 1,307 705,231 24,714 02/17/21
Lane Michael Executive Vice Presi.. Executive Vice President Feb 17 Option 0 984 4,768 02/17/21
Lane Michael Executive Vice Presi.. Executive Vice President Feb 17 Sell 545 850 463,250 3,624 02/17/21
Vandebroek Sophie V. Director Director Feb 16 Option 160.28 3,046 488,213 6,367 02/16/21
Vandebroek Sophie V. Director Director Feb 16 Sell 538.2 3,046 1,639,357 3,321 02/16/21
MCKEON BRIAN P Executive VP & CFO Executive VP & CFO Nov 10 Sell 475.43 10,000 4,754,300 18,050 11/10/20
MAZELSKY JONATHAN JAY President & CEO President & CEO Nov 09 Option 70.77 2,868 202,968 41,413 11/09/20